# AbCellera Biologics Inc. (ABCL)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.52B  
**Price:** $5.09 (-3.96%)

> AbCellera Biologics Inc. is a biotechnology company based in Vancouver, Canada, focused on discovering and developing therapeutic antibodies. The company operates a technology-driven antibody discovery platform that integrates biology, computation, and engineering to identify drug candidates from natural immune responses for a wide range of diseases. AbCellera’s platform searches, decodes, and analyzes immune systems at scale, aiming to generate high-quality antibody leads that can be advanced into clinical development by AbCellera or its partners. It collaborates with pharmaceutical and biotechnology companies to create antibody-based medicines across multiple indications and modalities, including complex and hard-to-drug targets. Founded in 2012 and headquartered in Vancouver, British Columbia, AbCellera Biologics Inc. plays a specialized role in the biopharmaceutical ecosystem as an innovation partner, providing discovery capabilities that support the development of new antibody therapeutics for global healthcare markets.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $75M | — | -$217M | -$146M | — |
| 2024 | $29M | — | -$315M | -$163M | — |
| 2023 | $38M | — | -$237M | -$146M | — |
| 2022 | $485M | — | $217M | $159M | — |
| 2021 | $375M | — | $204M | $153M | — |
| 2020 | $233M | — | $156M | $119M | — |
| 2019 | $12M | — | -$4M | -$2M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.36B | $390M | $967M | $129M | — |
| 2024 | $1.36B | $304M | $1.06B | $156M | — |
| 2023 | $1.49B | $336M | $1.15B | $133M | — |
| 2022 | $1.54B | $308M | $1.23B | $387M | — |
| 2021 | $1.32B | $293M | $1.03B | $476M | — |
| 2020 | $1.01B | $175M | $831M | $594M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$131M | $43M | -$174M |
| 2024 | -$109M | $78M | -$187M |
| 2023 | -$44M | $77M | -$121M |
| 2022 | $277M | $71M | $207M |
| 2021 | $245M | $58M | $186M |
| 2020 | $23M | $10M | $13M |
| 2019 | $3M | $4M | -$1M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ABCL)